ArticleMedicine2026
Complete locoregional response to radiotherapy and pembrolizumab in an elderly and frail patient with oropharyngeal squamous cell carcinoma: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleImmune checkpoint inhibitors (ICIs) have revolutionized the management of head and neck squamous cell carcinoma, particularly in the recurrent/metastatic setting. Although the combination of ICIs and radiotherapy (RT) in locally advanced disease has not yet demonstrated clear survival benefits, the strong biological rationale for their synergistic action continues to support investigation, especially in frail or elderly patients unfit for standard chemoradiotherapy. PATIENT CONCERNS: An 83-year-old male presented with odynophagia, dysphagia, significant weight loss, and right cervical swelling, all impairing oral intake and quality of life. DIAGNOSES: Moderately differentiated squamous cell carcinoma (G2) of the oropharynx (right base of tongue), human papillomavirus-negative, programmed death-ligand 1 combined positive score = 30. The tumor was staged as cT4a cN3b M1.
interventionsThe patient underwent hypofractionated RT (50 Gy in 20 fractions) delivering only to the primary lesion, followed by pembrolizumab 200 mg every 3 weeks. One pulmonary oligoprogressive lesion was treated with stereotactic body RT (60 Gy in 8 fractions). After 29 cycles of pembrolizumab, treatment was discontinued due to the onset of immune-related grade 3 hepatotoxicity. Two additional pulmonary oligoprogressive lesions were treated with stereotactic body radiotherapy, 55 Gy in 5 fractions. OUTCOMES: A complete response was achieved and maintained at both the primary tumor and nodal sites. Following immunotherapy discontinuation, liver biopsy confirmed immune-related cholangitis. Despite persistent elevation of cholestatic markers, disease control on T and N was preserved. A new pulmonary oligoprogression is currently under active surveillance. LESSONS: This case supports the hypothesis of synergism between RT and immunotherapy in an elderly and frail patient with advanced head and neck squamous cell carcinoma. Hypofractionated RT on the primary tumor alone, combined with ICIs, may lead to sustained locoregional control. Immune-related hepatic toxicity, while clinically significant, did not preclude stable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.